GENEDX HOLDINGS CORP. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.61 USD | +5.10% |
|
+1.77% | +659.73% |
| Apr. 30 | Health Care Flat Amid Mixed Earnings -- Health Care Roundup | DJ |
| Apr. 30 | Sector Update: Health Care Stocks Mixed Late Afternoon | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +613.09% | 513M | - | ||
| -24.66% | 7.76B | B+ | ||
| +68.65% | 4.33B | C+ | ||
| -3.15% | 2.64B | - | ||
| +3.74% | 2.63B | B- | ||
| -46.17% | 2.16B | B- | ||
| -15.27% | 1.75B | C- | ||
| -22.12% | 1.46B | A- | ||
| +13.62% | 1.17B | B+ | ||
| -43.81% | 1.14B | C+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- WGS Stock
- Ratings GeneDx Holdings Corp.
